Rehmann Capital Advisory Group Has $307,000 Position in Dynavax Technologies Co. (NASDAQ:DVAX)

Rehmann Capital Advisory Group grew its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 92.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 24,020 shares of the biopharmaceutical company’s stock after buying an additional 11,520 shares during the quarter. Rehmann Capital Advisory Group’s holdings in Dynavax Technologies were worth $307,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its position in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in shares of Dynavax Technologies by 463.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after buying an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in Dynavax Technologies in the 4th quarter valued at $71,000. Finally, Nisa Investment Advisors LLC grew its position in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 1,076 shares during the period. 96.96% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DVAX has been the subject of a number of analyst reports. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. HC Wainwright restated a “buy” rating and issued a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group dropped their price objective on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a report on Thursday, April 17th. Finally, StockNews.com raised Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $11.33 on Friday. The stock has a 50-day simple moving average of $12.59 and a 200 day simple moving average of $12.58. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 62.94 and a beta of 1.26. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 12-month low of $9.74 and a 12-month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The company had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. On average, research analysts anticipate that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.